Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 157,28€(+2,13%). Der Median liegt bei 157,28€(+2,13%).
Kaufen | 21 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | 0 / 13 |
News
FDA Accepts TransCon® CNP NDA for Priority Review
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo» Mehr auf globenewswire.com
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") are pleased to announce the successful completion of the previously announced plan of arrangement (the "Arrangement") under the Business Corporations Act (Ontario) pursuant to which Cerrado has acquired all of the issued and outstanding common shares of Ascendant ("Ascendant Shares") that it did not already own. The Arrangement was carried out pursuant to the terms of the arrangement agreement between Ascendant and Cerrado dated February 3, 2025, as amended, (the "Arrangement Agreement") and became effective on May 16, 2025, resulting in Ascendant becoming a wholly owned subsidiary of Cerrado.» Mehr auf accessnewswire.com
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") are pleased to announce the successful completion of the previously announced plan of arrangement (the "Arrangement") under the Business Corporations Act (Ontario) pursuant to which Cerrado has acquired all of the issued and outstanding common shares of Ascendant ("Ascendant Shares") that it did not already own. The Arrangement was carried out pursuant to the terms of the arrangement agreement between Ascendant and Cerrado dated February 3, 2025, as amended, (the "Arrangement Agreement") and became effective on May 16, 2025, resulting in Ascendant becoming a wholly owned subsidiary of Cerrado.» Mehr auf accessnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 100,95 Mio | 5,28% |
Bruttoeinkommen | 83,44 Mio | 5,53% |
Nettoeinkommen | −94,63 Mio | 27,79% |
EBITDA | −48,78 Mio | 4,03% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 8,59 Mrd€ |
Anzahl Aktien | 60,37 Mio |
52 Wochen-Hoch/Tief | 159,90€ - 97,07€ |
Dividenden | Nein |
Beta | 0,4 |
KGV (PE Ratio) | −25,04 |
KGWV (PEG Ratio) | −2,27 |
KBV (PB Ratio) | −45,08 |
KUV (PS Ratio) | 23,34 |
Unternehmensprofil
Ascendis Pharma A/S, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung von Therapeutika für ungedeckte medizinische Bedürfnisse. Das Unternehmen bietet SKYTROFA für die Behandlung von Patienten mit Wachstumshormonmangel (GHD) an. Außerdem entwickelt es TransCon Growth Hormone (hGH) für pädiatrische GHD in Japan, TransCon hGH für Erwachsene mit GHD, TransCon Parathyroid Hormon für Hypoparathyreoidismus bei Erwachsenen und TransCon CNP für pädiatrische Achondroplasie. Darüber hinaus entwickelt das Unternehmen TransCon Toll Like Receptors 7/8 Agonist für die intratumorale Verabreichung und TransCon IL-2 ß/g für die systemische Verabreichung. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Hellerup, Dänemark.
Name | Ascendis Pharma ADR |
CEO | Jan Moller Mikkelsen |
Sitz | Hellerup, Dänemark |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 1.017 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ASND |
Frankfurt | A71.F |
Düsseldorf | A71.DU |
München | A71.MU |
Assets entdecken
Shareholder von Ascendis Pharma ADR investieren auch in folgende Assets